The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Certolizumab Pegol for Active Crohn's Disease: A Placebo-Controlled, Randomized Trial
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Targan, S. R., Hanauer, S. B., van Deventer, S. J. H., Mayer, L., Present, D. H., Braakman, T., DeWoody, K. L., Schaible, T. F., & Rutgeerts, P. J. (1997) · New England Journal of Medicine · doi:10.1056/nejm199710093371502 · Cited by 3,135
Self-citationSu, C., Lichtenstein, G. R., Krok, K., Brensinger, C. M., & Lewis, J. D. (2004) · Gastroenterology · doi:10.1053/j.gastro.2004.01.024 · Cited by 212
Cited by
ECCO Guidelines on Therapeutics in Crohn’s Disease: Medical Treatment
Gordon, H., Minozzi, S., Kopylov, U., Verstockt, B., Chaparro, M., Buskens, C., Warusavitarne, J., Agrawal, M., Allocca, M., Atreya, R., et al. (2024) · Journal of Crohn's and Colitis · doi:10.1093/ecco-jcc/jjae091 · Cited by 388
Bonovas, S., Fiorino, G., Allocca, M., Lytras, T., Nikolopoulos, G. K., Peyrin-Biroulet, L., & Danese, S. (2016) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2016.04.039 · Cited by 387
Vincent, F. B., Morand, E. F., Murphy, K., Mackay, F., Mariette, X., & Marcelli, C. (2013) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2012-202545 · Cited by 356
Immunogenicity of Biologics in Chronic Inflammatory Diseases: A Systematic Review
Strand, V., Balsa, A., Al-Saleh, J., Barile-Fabris, L., Horiuchi, T., Takeuchi, T., Lula, S., Hawes, C., Kola, B., & Marshall, L. (2017) · BioDrugs · doi:10.1007/s40259-017-0231-8 · Cited by 353
Ford, A. C., & Peyrin-Biroulet, L. (2013) · American Journal of Gastroenterology · doi:10.1038/ajg.2013.138 · Cited by 343
Mechanism of Action of Anti-TNF Therapy in Inflammatory Bowel Disease
Levin, A. D., Wildenberg, M. E., & van den Brink, G. R. (2016) · Journal of Crohn's and Colitis · doi:10.1093/ecco-jcc/jjw053 · Cited by 336
Molecular mechanisms of action of anti-TNF-α agents – Comparison among therapeutic TNF-α antagonists
Mitoma, H., Horiuchi, T., Tsukamoto, H., & Ueda, N. (2018) · Cytokine · doi:10.1016/j.cyto.2016.08.014 · Cited by 316
Bharadwaj, U., Kasembeli, M. M., Robinson, P., & Tweardy, D. J. (2020) · Pharmacological Reviews · doi:10.1124/pr.119.018440 · Cited by 314
“Anti-TNF antibodies that disrupt the interaction of TNF-awith its receptor, including infliximab (a mouse–human chimeric anti–TNF-a antibody), adalimumab (a humanmonoclonal anti–TNF-a antibody), and certolizumab pegol (recombinant humanized anti–TNF-a antibody), appear to be beneficial in CD patients (Targan et al., 1…”
BackgroundA Phase 2 Study of Tofacitinib, an Oral Janus Kinase Inhibitor, in Patients With Crohn’s Disease
Sandborn, W. J., Ghosh, S., Panes, J., Vranic, I., Wang, W., Niezychowski, W., Vermeire, S. A. R. A., Dewit, O., Peeters, H., Stehlik, J., et al. (2014) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2014.01.029 · Cited by 300
Self-citationSingh, S., Murad, M. H., Fumery, M., Sedano, R., Jairath, V., Panaccione, R., Sandborn, W. J., & Ma, C. (2021) · The Lancet Gastroenterology & Hepatology · doi:10.1016/s2468-1253(21)00312-5 · Cited by 298
Self-citationDassopoulos, T., Sultan, S., Falck–Ytter, Y. T., Inadomi, J. M., & Hanauer, S. B. (2013) · Gastroenterology · doi:10.1053/j.gastro.2013.10.046 · Cited by 297
Singh, S., Facciorusso, A., Singh, A. G., Casteele, N. V., Zarrinpar, A., Prokop, L. J., Grunvald, E. L., Curtis, J. R., & Sandborn, W. J. (2018) · PLOS ONE · doi:10.1371/journal.pone.0195123 · Cited by 293
Self-citationGisbert, J. P., & Chaparro, M. (2020) · Journal of Crohn's and Colitis · doi:10.1093/ecco-jcc/jjz195 · Cited by 281
Hazlewood, G. S., Rezaie, A., Borman, M., Panaccione, R., Ghosh, S., Seow, C. H., Kuenzig, E., Tomlinson, G., Siegel, C. A., Melmed, G. Y., et al. (2015) · Gastroenterology · doi:10.1053/j.gastro.2014.10.011 · Cited by 276
Anti-TNF Therapy in Crohn’s Disease
Adegbola, S. O., Sahnan, K., Warusavitarne, J., Hart, A., & Tozer, P. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19082244 · Cited by 274
Biomarkers in inflammatory bowel disease: current practices and recent advances.
Iskandar, H. N., & Ciorba, M. A. (2012) · Translational Research · doi:10.1016/j.trsl.2012.01.001 · Cited by 210
“(10, 11) These high placebo rates lead to difficulty in demonstrating treatment efficacy, as evidenced by a recent trial of certolizumab in CD, where the use of biomarkers as objective measures of disease activity may have enhanced the ability to reach statistical significance.(12) In UC, mucosal healing can be assess…”
ResultMagro, F., Moreira, P. L., Catalano, G., Alves, C., Roseira, J., Estevinho, M. M., Silva, I., Dignass, A., Peyrin‐Biroulet, L., Danese, S., et al. (2023) · United European Gastroenterology Journal · doi:10.1002/ueg2.12366 · Cited by 30
Metadata
- Authors
- Sandborn, W. J., Schreiber, S., Feagan, B. G., Rutgeerts, P., Younes, Z. H., Bloomfield, R., Coteur, G., Guzman, J. P., & D'Haens, G. R.
- Venue
- Clinical Gastroenterology and Hepatology
- Publisher
- Elsevier BV
- Published
- 2011-08
- Volume
- 9
- Issue
- 8
- Pages
- 670-678.e3
- ISSN
- 1542-3565 (ISSN-L)
- OpenAlex
- W2056348171
- Cited by
- 175
- References
- 2
- FWCI
- 8.95
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.